drugset / Trial / NCT00039429
Atrasentan in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer
Phase 2
Completed
180 enrolled
Eastern Cooperative Oncology Group
National Cancer Institute (NCI) · collab
Open-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well atrasentan works in treating patients with locally recurrent or metastatic kidney cancer.
Timeline
- Start
- 2003-07-14
- Primary completion
- 2006-04
- Completion
- —
Publications
- Results Manola J, Carducci M, Nair S, et al.: Phase II ECOG trial of atrasentan in advanced renal cell carcinoma. [Abstract] J Clin Oncol 25 (Suppl 18): A-5102, 260s, 2007.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atrasentan | Other / unclassified | — | Oral |